1. A pharmaceutical combination for use in glycemic control in patients with type 2 diabetes, wherein said combination comprises (a) desProeksendin-4 (1-39) -Lys-NHi / or a pharmaceutically acceptable salt thereof, (b) a basal insulin, and / or a pharmaceutically acceptable salt thereof and (c) optionally, metformin and / or a pharmaceutically acceptable salt thereof, wherein the patient to be treated has a concentration of glucose in plasma 2 hours after ingestion, of at least 12 mmol / l, and wherein type 2 diabetes to be treated is not adequately controlled by insulin alone basal and optionally metforminom.2. The pharmaceutical combination of claim 1 wherein the patient to be treated has a fluctuation of glucose levels of at least 2 mmol / l, at least 3 mmol / l, at least 4 mmol / l or at least 5 mmol / l where glucose is the fluctuation difference in the plasma glucose concentration at 2 hours post-prandial glucose and plasma concentration at 30 minutes before the test pischi.3 reception. Pharmaceutical combination according to claim 1 or 2 wherein the patient to be treated suffers ozhireniem.4. Pharmaceutical combination according to claim 1 or 2 wherein the patient to be treated has a body mass index of at least 30 kg / M.5. Pharmaceutical combination according to claim 1 or 2 wherein the patient to be treated is adult chelovek.6. Pharmaceutical combination according to claim 1 or 2, wherein the patient to be treated, type 2 diabetes mellitus was diagnosed at least 1 year or at least 2 years before the terapii.7. Pharmaceutical combination according to claim 1 or 2 wherein the patient to be treated has a value of HbA, of from about 7 to pr1. Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с диабетом 2 типа, где указанная комбинация содержит(a) desPro36эксендин-4(1-39)-Lys6-NH2 и/или его фармацевтически приемлемую соль,(b) базальный инсулин и/или его фармацевтически приемлемую соль и(c) необязательно, метформин и/или его фармац
